2018
DOI: 10.1016/j.nucmedbio.2018.06.001
|View full text |Cite
|
Sign up to set email alerts
|

Matched-pair, 86Y/90Y-labeled, bivalent RGD/bombesin antagonist, [RGD-Glu-[DO3A]-6-Ahx-RM2], as a potential theranostic agent for prostate cancer

Abstract: The theranostic, heterobivalent, agents described herein perform comparably with other mono- and multivalent conjugates we have reported and offer the potential of improved sensitivity for detecting prostate cancer cells that might exhibit differing profiles of receptor expression on tumor cells in human patients.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
15
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 17 publications
(15 citation statements)
references
References 23 publications
0
15
0
Order By: Relevance
“…86 Y ( T 1/2 = 14.7 h) decays by electron capture (EC) (66%) and β + (34%) with E β + max = 3.2 MeV and has been used as a PET imaging surrogate for the therapeutic radionuclide 90 Y . It can be produced in low‐energy cyclotrons via the reaction 86 Sr(p,n) 86 Y or 86 Sr(d,2n) 86 Y using carbonate or oxide targets .…”
Section: Radiometals For Theranostic Applicationsmentioning
confidence: 99%
See 4 more Smart Citations
“…86 Y ( T 1/2 = 14.7 h) decays by electron capture (EC) (66%) and β + (34%) with E β + max = 3.2 MeV and has been used as a PET imaging surrogate for the therapeutic radionuclide 90 Y . It can be produced in low‐energy cyclotrons via the reaction 86 Sr(p,n) 86 Y or 86 Sr(d,2n) 86 Y using carbonate or oxide targets .…”
Section: Radiometals For Theranostic Applicationsmentioning
confidence: 99%
“…39,40 In particular, the therapeutic utility of 90 Y-labelled somatostatin-receptor targeting peptides, when used either alone 41,42 or in combination therapy, [43][44][45] has been demonstrated over the last two decades. 86 46 It can be produced in low-energy cyclotrons via the reaction 86 Sr(p,n) 86 Y or 86 Sr(d,2n) 86 Y using carbonate or oxide targets. 47 However, the targetry is challenging, and the physical properties of 86 Y have some limitations, such as the high-energy gamma emission (more than 65% of 86 Y decays are accompanied by additional γ-rays with energies from 200 to 3000 keV), 48 which contribute to the patient radiation dose.…”
Section: Gamentioning
confidence: 99%
See 3 more Smart Citations